APA (7th ed.) Citation

A, B., J, B., A, P., D, T., M, Z., J, C., . . . J, F. (2026). Repeated switching between biosimilar ABP 654 and reference ustekinumab in patients with moderate-to-severe plaque psoriasis: A randomized, double-blinded clinical trial to support interchangeability. The British journal of dermatology. https://doi.org/10.1093/bjd/ljag218

Chicago Style (17th ed.) Citation

A, Blauvelt, Bagel J, Pinter A, Thaçi D, Zhou M, Cao J, Mytych DT, Chow V, and Franklin J. "Repeated Switching Between Biosimilar ABP 654 and Reference Ustekinumab in Patients with Moderate-to-severe Plaque Psoriasis: A Randomized, Double-blinded Clinical Trial to Support Interchangeability." The British Journal of Dermatology 2026. https://doi.org/10.1093/bjd/ljag218.

MLA (9th ed.) Citation

A, Blauvelt, et al. "Repeated Switching Between Biosimilar ABP 654 and Reference Ustekinumab in Patients with Moderate-to-severe Plaque Psoriasis: A Randomized, Double-blinded Clinical Trial to Support Interchangeability." The British Journal of Dermatology, 2026, https://doi.org/10.1093/bjd/ljag218.